{"id":7127,"date":"2020-02-17T10:37:30","date_gmt":"2020-02-17T10:37:30","guid":{"rendered":"https:\/\/www.healthbenefitstimes.com\/glossary\/?p=7127"},"modified":"2020-02-17T10:37:30","modified_gmt":"2020-02-17T10:37:30","slug":"receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl","status":"publish","type":"post","link":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/","title":{"rendered":"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)"},"content":{"rendered":"<p>A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.<\/p>\n<hr \/>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18],"tags":[],"class_list":["post-7127","post","type-post","status-publish","format-standard","hentry","category-r"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Receptor activator of nuclear factor\u2010kappa B ligand (RANKL) - Definition of Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)<\/title>\n<meta name=\"description\" content=\"A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor\u2010kappa-b-ligand-rankl\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL) - Definition of Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)\" \/>\n<meta property=\"og:description\" content=\"A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor\u2010kappa-b-ligand-rankl\/\" \/>\n<meta property=\"og:site_name\" content=\"Glossary\" \/>\n<meta property=\"article:published_time\" content=\"2020-02-17T10:37:30+00:00\" \/>\n<meta name=\"author\" content=\"Glossary\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Glossary\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/\",\"name\":\"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL) - Definition of Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)\",\"isPartOf\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\"},\"datePublished\":\"2020-02-17T10:37:30+00:00\",\"dateModified\":\"2020-02-17T10:37:30+00:00\",\"author\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\"},\"description\":\"A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#website\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/\",\"name\":\"Glossary\",\"description\":\"Difinitions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5\",\"name\":\"Glossary\",\"url\":\"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL) - Definition of Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)","description":"A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor\u2010kappa-b-ligand-rankl\/","og_locale":"en_US","og_type":"article","og_title":"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL) - Definition of Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)","og_description":"A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.","og_url":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor\u2010kappa-b-ligand-rankl\/","og_site_name":"Glossary","article_published_time":"2020-02-17T10:37:30+00:00","author":"Glossary","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Glossary","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/","name":"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL) - Definition of Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)","isPartOf":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website"},"datePublished":"2020-02-17T10:37:30+00:00","dateModified":"2020-02-17T10:37:30+00:00","author":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5"},"description":"A 317\u2010amino acid peptide, member of the tumor necrosis factor (TNF) superfamily, that stimulates osteoclast differentiation and activity as well as inhibiting osteoclast apoptosis. It is expressed by osteoblast\u2010stromal cells, fibroblasts, and activated T cells. In the bone tissue, RANKL binds directly to its receptor (i.e., receptor activator of nuclear factor\u2010kappa B [RANK]) on the surface of osteoclasts or preosteoclasts, stimulating both the differentiation of osteoclast progenitor cells and the activity of mature osteoclasts. It exists as either a 40\u201345 kD cellular, membrane\u2010bound form or a 31 kD soluble form derived by cleavage of the full\u2010length form at position 140 or 145. It also has a number of effects on immune cells, including activation of c\u2010Jun N\u2010terminal kinase (JNK) in T cells, inhibition of apoptosis of dendritic cells, induction of cluster formation by dendritic cells, and proliferation of cytokine\u2010activated T cells.","breadcrumb":{"@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/receptor-activator-of-nuclear-factor%e2%80%90kappa-b-ligand-rankl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.healthbenefitstimes.com\/glossary\/"},{"@type":"ListItem","position":2,"name":"Receptor activator of nuclear factor\u2010kappa B ligand (RANKL)"}]},{"@type":"WebSite","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#website","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/","name":"Glossary","description":"Difinitions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.healthbenefitstimes.com\/glossary\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.healthbenefitstimes.com\/glossary\/#\/schema\/person\/ccfef987a4882e6356ae6d77d33e74c5","name":"Glossary","url":"https:\/\/www.healthbenefitstimes.com\/glossary\/author\/adminglossary\/"}]}},"_links":{"self":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/7127","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/comments?post=7127"}],"version-history":[{"count":1,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/7127\/revisions"}],"predecessor-version":[{"id":7128,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/posts\/7127\/revisions\/7128"}],"wp:attachment":[{"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/media?parent=7127"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/categories?post=7127"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.healthbenefitstimes.com\/glossary\/wp-json\/wp\/v2\/tags?post=7127"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}